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From 2007 to 2009, the Netherlands faced large sea-
sonal outbreaks of Q fever, in which infected dairy 
goat farms were identified as the primary sources. 
Veterinary measures including vaccination of goats 
and sheep and culling of pregnant animals on infected 
farms seem to have brought the Q fever problem under 
control. However, the epidemic is expected to result in 
more cases of chronic Q fever among risk groups in the 
coming years. In the most affected area, in the south 
of the country, more than 12% of the population now 
have antibodies against Coxiella burnetii. Questions 
remain about the follow-up of acute Q fever patients, 
screening of groups at risk for chronic Q fever, screen-
ing of donors of blood and tissue, and human vaccina-
tion. There is a considerable ongoing research effort as 
well as enhanced veterinary and human surveillance.
Introduction
Acute Q fever was made mandatorily notifiable in the 
Netherlands in 1975, but was rarely reported from 
1975 to 2006 (with between one and 32 notifications 
per year). In 2005, Q fever was diagnosed on two dairy 
goat farms with unusually high numbers of abortions 
and two years later, in 2007, it emerged in the human 
population in the south of the Netherlands. This 
was the start of an exceptionally large epidemic that 
showed a marked seasonality and expanded both geo-
graphically and in size in 2008 and 2009. From 2007 
to 2009, more than 3,500 human cases were notified. 
The observation that human cases mainly occurred in 
the same area as dairy goat farms with Q fever-induced 
abortion waves provided circumstantial evidence that 
dairy goat farms were the most plausible source of 
human infection in this epidemic. The patients most 
affected were men, smokers and aged 40–60 years, 
while children were rarely affected [1]. Acute Q fever 
mainly presents as febrile illness, pneumonia or hepa-
titis, but clinical presentation may vary from one area 
to another [2]. More than 92% of notified patients in 
the Netherlands with onset of illness in 2007 and 
2008 had fever, while 62% presented with pneumonia 
[1]. Hepatitis was reported in less than 1% of notified 
patients but is a common presentation of acute Q fever 
in some countries such as France [2]. The diagnosis Q 
fever can only be made after confirmation with a labo-
ratory test. Serological methods can detect antibodies 
against phase I and phase II antigens of Coxiella bur-
netii, the causative agent of Q fever, and thereby dis-
tinguish acute from chronic disease. Annual updates 
on the Q fever epidemic in the Netherlands have been 
published in this journal [3-5]. We now report on the 
current situation in the aftermath of the epidemic, 
focusing on the challenges and remaining questions, 
especially with respect to chronic Q fever.
Decreasing incidence of acute Q fever,  
increasing seroprevalence
The epidemiological situation in the aftermath of the 
epidemic can be characterised by a decreased inci-
dence of notifications of acute Q fever and an increased 
prevalence of antibodies to C.  burnetii in the general 
population, particularly in the most affected area in the 
south of the country. The number of notified acute Q 
fever patients fell from 2,354 in 2009 to 504 in 2010 
(Figure). From January to November 2011, 81 patients 
were notified, which is far fewer than the same period 
in the epidemic years, despite the exceptionally warm 
and dry weather conditions in the spring of 2011, 
which are considered conducive to airborne spread of 
C. burnetii.
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It is difficult to attribute the decrease in incidence 
in 2010 and 2011 to any particular control measure 
because several veterinary interventions were imple-
mented at the same time. In April 2009, vaccination 
of sheep and goats on dairy farms with more than 50 
animals and on farms with public functions in the high-
incidence area became mandatory and was extended 
to the entire country in January 2010 [6]. In addi-
tion, stringent hygiene measures were implemented, 
such as safe manure management and hygiene dur-
ing lambing. In October 2009, mandatory monitoring 
of bulk tank milk was implemented. In addition, from 
December 2009 to June 2010, more than 50,000 preg-
nant goats and sheep were culled on 87 farms in which 
bulk tank milk was positive for C. burnetii.
Increasing immunity and thereby a smaller popula-
tion at risk among the general population in the high-
incidence area might also have played a role in the 
decrease in incidence of acute Q fever. Seroprevalence 
among the general population of the Netherlands was 
only 2.4% during February 2006 to May 2007, before 
the first outbreak in June 2007 [7]. More recent nation-
wide figures are not available, but in the high-incidence 
area, seroprevalence estimates are available for preg-
nant women in 2007 to 2009 (9.0%) [8] and for blood 
donors in 2009 (12.2%) [9].
Chronic Q fever
Despite the decreasing incidence of acute Q fever, the 
Q fever problem is not over: a rising number of chronic 
Q fever patients are seen. An estimated 2% of acute Q 
fever patients develop chronic Q fever months to years 
after the acute infection [10]. Chronic Q fever mainly 
presents as endocarditis or vascular infection and car-
ries a high morbidity and mortality. Infected patients 
with previous cardiac valve pathology, aneurysms or 
vascular grafts or who are immunocompromised and 
women who are infected during pregnancy are most 
at risk of developing chronic Q fever [2]. Diagnosis of 
chronic Q fever is based on a combination of the follow-
ing: PCR analysis positive for C. burnetii in blood or tis-
sue in the absence of an acute infection, an IgG phase I 
antibody titre of ≥1:1,024, presence of clinical risk fac-
tors, presence of clinical signs, and radiological imag-
ing results including echocardiography and positron 
emission tomography-computed tomography (PET-CT) 
[11]. There is no notification system for chronic Q fever 
in the Netherlands, but based on personal communica-
tions from various Dutch hospitals in September 2011, 
we estimate that a total of over 250 patients have been 
diagnosed since the start of the epidemic.
The major challenge in the Netherlands is therefore 
early detection and treatment of patients who are at 
risk for chronic Q fever. The following issues are of par-
ticular relevance: (i) the follow-up strategy of acute Q 
fever patients, for the early detection and prompt treat-
ment of chronic Q fever; (ii) the screening of people in 
risk groups for chronic Q fever; (iii) the protection of 
people in risk groups through vaccination; and (iv) the 
possibility of person-to-person transmission through 
infected blood or tissue.
Figure 
Acute Q fever notifications, the Netherlands, 1 January (week 1) 2007–30 November (week 48) 2011
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It is expected that the number of patients with chronic 
infection will increase in the Netherlands the coming 
years. In order to diagnose and treat chronic Q fever 
patients in a consistent way, new guidelines are cur-
rently being developed for the diagnosis of chronic Q 
fever in the country.
Follow-up of acute Q fever patients
In the early stages of the epidemic, the internationally 
recommended follow-up strategy was followed, con-
sisting of at least three consecutive serological tests 
in the first year after the diagnosis of acute Q fever and 
echocardiography for all patients diagnosed with acute 
Q fever [12]. However, of 134 Dutch Q fever patients 
from the 2007 and 2008 outbreaks who had undergone 
screening echocardiography and were followed up for 
one year after diagnosis of acute infection, none pro-
gressed to a chronic infection and echocardiographic 
screening was discontinued [13]. However, the policy of 
discontinuing echocardiographic screening has been 
challenged by Raoult et al., on the basis of data from 
France that show that clinically silent valvulopathies 
predispose to chronicity [14]. Considerable uncertain-
ties also exist about the value of serology to identify 
chronic cases during follow-up. At the regional labora-
tory of the Jeroen Bosch Hospital (in s´-Hertogenbosch), 
located at the epicentre of the Dutch outbreaks, the 
serological profiles of 686 patients diagnosed with 
acute Q fever in 2007 and 2008 were evaluated at three, 
six and 12 months after diagnosis [15]. The results dif-
fer from data provided by others, as high IgG phase I 
antibody titres at the three-month follow-up were not 
predictive for chronic Q fever and IgG phase I antibody 
titres greater than IgG phase II antibody titres were 
rarely seen. The study confirmed that a cut-off value of 
≥1:1,024 for IgG phase I titres is suitable for screening in 
the commercially available immunofluorescence assay 
used (Focus Diagnostics, United States), at a follow-up 
between six and 12 months after the acute Q fever epi-
sode. For patients with clinical risk factors, however, 
a more stringent follow-up scheme is required. Wide 
variation in serological and PCR test results during the 
follow-up of acute Q fever [15] implies that the diagno-
sis of chronic Q fever – necessitating long-term anti-
biotic treatment – must be based on a combination of 
laboratory results, radiological imaging and clinical 
grounds. On the basis of the experience gained since 
2007, the follow-up strategy is now generally one sero-
logical analysis nine months after an episode of acute 
Q fever. For patients with specific risk factors, the pre-
vious serological follow-up strategy at three, six and 
12 months is maintained, with use of PCR if high IgG I 
titres are obtained.
Screening of risk groups for chronic Q fever
Chronic Q fever has been diagnosed in the Netherlands 
in patients who had no history of acute Q fever, sug-
gesting that chronic Q fever can develop after asympto-
matic infection or symptomatic infection with only mild 
aspecific symptoms. The incubation period of a chronic 
infection is largely unknown and may be different in 
patients with vascular disease compared with those 
who have valvular disease. Some hospitals in the 
high-incidence area are now implementing screening 
programmes for the detection of chronic Q fever in 
patients with known cardiac valve or vascular pathol-
ogy. The risk of chronic Q fever in other risk groups, 
such as pregnant women, is probably too low to war-
rant a targeted screening strategy.
Human vaccination
Q fever can be prevented by a vaccine that is produced 
and licensed in Australia to protect abattoir workers 
[16]. For this and other occupational risk groups, such 
as sheep shearers and farmers of ruminants, the vac-
cine has proved to be successful and is still in use in 
Australia [17]. From the notification data, it is clear that 
occupational exposure did not play an important role 
in the epidemic in the Netherlands [1]. The prevalence 
of antibodies against C.  burnetii in dairy goat farm-
ers and practising veterinarians is greater than 80%, 
but very few seem to develop clinical disease (unpub-
lished data). Vaccination – a one-off campaign during 
the epidemic – was therefore primarily considered for 
persons at risk for chronic Q fever. Implementing vac-
cination was difficult, however, because the vaccine is 
not registered in any European country and its effec-
tiveness has only been shown in healthy young adults, 
not in persons with cardiovascular risk factors or 
patients with severe underlying disease [18]. Moreover, 
the logistics are cumbersome: the vaccine can only be 
given to those who have not previously been in con-
tact with C.  burnetii, as vaccinating people who have 
already mounted an immune response against the 
pathogen may lead to serious adverse reactions such 
as sterile abscesses and systemic symptoms of inflam-
mation. Therefore, serology and skin testing are man-
datory before vaccination. In the absence of a licence, 
the vaccine can only be administered after the patients’ 
physician has signed a medical awareness statement 
and the patient has signed an informed consent form. 
Nevertheless, the Health Council of the Netherlands 
advised vaccination of people in specific risk groups 
in the high-incidence area who have an increased risk 
of developing complications following acute infection 
[19]. The groups included patients:
•	 who have had endocarditis
•	 with prosthetic heart valves
•	 with important congenital heart anomalies, includ-
ing those that required grafts
•	 with structural defects of the aortic or mitral valve
•	 with known aneurysm of the aorta
•	 with vascular grafts
•	 with severe peripheral vascular disease (such as 
Buerger’s disease).
General practitioners selected all patients from these 
groups from their patient registration systems. In 
total, 1,781 patients were screened: 394 (22%) could 
not be vaccinated because of a positive skin test or 
the presence of antibodies against C.  burnetii. After 
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screening, 21 eligible patients declined vaccination 
or did not attend the vaccination session: eventually 
1,366 patients were vaccinated from 28 January to 27 
June 2011. There is a routine follow-up of vaccinated 
individuals for vaccine-related adverse events – the 
results should be available by the end of 2011. The vac-
cination campaign has also been followed by a post-
vaccination immune-response study in which humoral 
and cell-mediated immunity will be investigated.
Transmission of C. burnetii by infected 
blood and tissue
Although only few cases have been clearly documented, 
there is a theoretical possibility that C. burnetii can be 
transmitted through blood transfusion, and semen, 
tissue and organ donation [20]. Active screening 
was therefore recommended by the European Centre 
for Disease Prevention and Control (ECDC) in their 
risk assessment in 2010 [10]. Sanquin Blood Supply 
Foundation tested blood donated from people living in 
the area with highest Q fever incidence in the south of 
the Netherlands for the presence of C. burnetii DNA by 
PCR from 20 May 2009 – in 2009 as part of a research 
project, then in 2010 as a screening instrument [9]. 
In 1,004 blood donations, there were three positive 
PCR results and in one recipient, there was evidence 
of seroconversion. However, the recipient lived in the 
high-incidence area and it is therefore possible that 
the infection was caused by environmental exposure. 
The screening programme was discontinued on 1 
November 2010, when it was clear that the incidence of 
the disease had fallen dramatically. With the decreas-
ing incidence and the expected increasing numbers of 
chronic infections in the coming years, the issue of pro-
tecting recipients of blood, semen, tissue and organs 
is shifting towards detecting asymptomatic persons 
harbouring C. burnetii months to years after their acute 
infection. However, there are important logistic and 
financial constraints in using PCR on a large scale. 
Capacity for PCR testing at Sanquin is limited to 100 
samples per day, while close to a million blood com-
ponent transfusions are given annually. Alternatively, 
donors could be screened for the presence of IgG 
phase I antibodies against C.  burnetii. For large-scale 
screening purposes, an automated ELISA would have to 
be used, but the performance of ELISAs for IgG phase I 
antibodies have yet to be evaluated.
In August 2011, the Health Council of the Netherlands 
advised that a detailed cost-effectiveness analysis of 
serological testing of blood donors be carried out and, 
should the incidence of acute Q fever increase again, 
screening of blood donors be resumed [20]. Concerning 
tissue donations, no screening is needed for tissues 
that carry a low risk of transmission such as cornea, 
coagulants and other treated blood products or tissues 
collected before 2007. Otherwise, nationwide serologi-
cal testing is recommended. In certain circumstances, 
such as organ transplantation or use of stem cells, 
the responsible physician and patient might decide 
to use infected material anyway, when a considerable 
improvement in quality of life or even the saving of life 
is anticipated. Knowing that the donor’s serological 
status is positive can then make appropriate antibiotic 
prophylactic treatment of the recipient possible.
Persistent fatigue after acute Q fever
While relatively few patients who have had acute infec-
tion develop chronic Q fever, a much larger group suf-
fers from persistent fatigue and other long-term effects 
of acute infection. Unlike chronic Q fever, this is not a 
life-threatening condition, but the fatigue can be debil-
itating and seriously affect the person’s quality of life 
[21]. In an ongoing study, the effectiveness of antibi-
otic treatment is being compared with cognitive behav-
ioural therapy for post acute Q fever fatigue.
Outlook
We expect that the sustained mandatory vaccination 
of goats and sheep will control transmission of Q fever 
to humans. The veterinary vaccine seems effective 
in reducing shedding of C.  burnetii and in preventing 
abortion [22]. However, the bacteria are widespread in 
the environment and in other animal reservoirs, such as 
wild rats [23]. Enhanced surveillance in animal popula-
tions as well as in humans will remain essential. To fill 
the remaining knowledge gaps, there is an extensive 
ongoing research agenda, covering fields such as as 
host–pathogen characteristics, transmission and risk 
factors, chronic Q fever and treatment of post acute Q 
fever fatigue.
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